On August 28, 2024, Healgen Scientific inaugurated its largest manufacturing facility in south Houston, which is set to produce over 800,000 tests daily for COVID-19, flu, and RSV. This new facility adds to Healgen's existing 120-person workforce, creating an additional 60 jobs, and is part of a broader expansion that includes a new headquarters in Katy, Texas [ad41528f].
Healgen operates 325 production lines globally, with 15 located in the United States. The tests produced at this facility will be marketed under the Siemens Clinitest brand and have received FDA approval, enhancing the availability of reliable testing options in the region. The total production capacity of Healgen now exceeds 22 million tests daily, significantly bolstering the testing infrastructure in response to ongoing health challenges [ad41528f].
State Representative Gene Wu emphasized the contributions of Chinese Americans to the Texas economy during the facility's opening ceremony, highlighting the importance of diversity in the workforce. Healgen has also made significant tax contributions, paying over $25 million in federal taxes and $9 million in state taxes, reflecting its commitment to the local economy [ad41528f].
This new facility not only aims to meet the rising demand for COVID-19 testing but also addresses the need for flu and RSV testing, which are crucial as the seasons change. The establishment of this facility is a vital step towards ensuring public health safety and enhancing the state's response capabilities against respiratory illnesses [ad41528f].